




Instance: composition-en-f5fcc043447c207ce2e1eb4575399a55
InstanceOf: CompositionUvEpi
Title: "Composition for betmiga Package Leaflet"
Description:  "Composition for betmiga Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/12/809/001 - 006"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf5fcc043447c207ce2e1eb4575399a55)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - betmiga"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Betmiga is and what it is used for </li>
<li>What you need to know before you take Betmiga </li>
<li>How to take Betmiga </li>
<li>Possible side effects </li>
<li>How to store Betmiga </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What betmiga is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What betmiga is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Betmiga contains the active substance mirabegron. It is a bladder muscle relaxant (a so called 
beta 3-adrenoceptor agonist), which reduces the activity of an overactive bladder and treats the related 
symptoms. </p>
<p>Betmiga is used to treat the symptoms of an overactive bladder in adults such as:</p>
<ul>
<li>suddenly needing to empty your bladder (called urgency) </li>
<li>having to empty your bladder more than usual (called increased urinary frequency) </li>
<li>not being able to control when to empty your bladder (called urgency incontinence) </li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take betmiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take betmiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Betmiga:</p>
<ul>
<li>if you are allergic to mirabegron or any of the other ingredients of this medicine (listed in 
section 6) </li>
<li>if you have very high uncontrolled blood pressure. </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Betmiga:</p>
<ul>
<li>if you have trouble emptying your bladder or you have a weak urine stream or if you take other 
medicines for the treatment of overactive bladder such as anticholinergic medicines. </li>
<li>if you have kidney or liver problems. Your doctor may need to reduce your dose or may tell you 
not to take Betmiga, especially if you are taking other medicines such as itraconazole, 
ketoconazole (fungal infections), ritonavir (HIV/AIDS) or clarithromycin (bacterial infections). 
Tell your doctor about the medicines that you take. </li>
<li>if you have an ECG (heart tracing) abnormality known as QT prolongation or you are taking 
any medicine known to cause this such as: * medicines used for abnormal heart rhythm such as quinidine, sotalol, procainamide, 
ibutilide, flecainide, dofetilide, and amiodarone; * medicines used for allergic rhinitis; * antipsychotic medicines (medicines for mental illness) such as thioridazine, 
mesoridazine, haloperidol, and chlorpromazine; * anti-infectives such as pentamidine, moxifloxacin, erythromycin, and clarithromycin. </li>
</ul>
<p>Mirabegron may cause your blood pressure to increase or make your blood pressure worse if you have 
a history of high blood pressure. It is recommended that your doctor check your blood pressure while 
you are taking Mirabegron. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents under the age of 18 years because the safety and 
efficacy of Betmiga in this age group has not been established. </p>
<p>Other medicines and Betmiga 
Tell your doctor or pharmacist if you are taking, have recently used or might use any other medicines. </p>
<p>Betmiga may affect the way other medicines work, and other medicines may affect how this medicine 
works. 
- Tell your doctor if you use thioridazine (a medicine for mental illness), propafenone or 
flecainide (medicines for abnormal heart rhythm), imipramine or desipramine (medicines used 
for depression). These specific medicines may require dose adjustment by your doctor. 
- Tell your doctor if you use digoxin (a medicine for heart failure or abnormal heart rhythm). 
Blood levels of this medicine are measured by your doctor. If the blood level is out of range, 
your doctor may adjust the dose of digoxin. 
- Tell your doctor if you use dabigatran etexilate (a medicine which is used to reduce the risk of 
brain or body vessel obstruction by blood clot formation in adult patients with an abnormal 
heart beat (atrial fibrillation) and additional risk factors). This medicine may require dose 
adjustment by your doctor. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant, think you may be pregnant or are planning to have a baby you should not take 
Betmiga. </p>
<p>If you are breast-feeding, ask your doctor or pharmacist for advice before taking this medicine. It is 
likely that this medicine passes into your breast milk. You and your doctor should decide if you should 
take Betmiga or breastfeed. You should not do both. </p>
<p>Driving and using machines 
There is no information to suggest that this medicine affects your ability to drive or use machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take betmiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take betmiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>The recommended dose is one 50 mg tablet by mouth once daily. If you have kidney or liver 
problems, your doctor may need to reduce your dose to one 25 mg tablet by mouth once daily. You 
should take this medicine with liquids and swallow the tablet whole. Do not crush or chew the tablet. 
Betmiga can be taken with or without food. </p>
<p>If you take more Betmiga than you should 
If you have taken more tablets than you have been told to take, or if someone else accidentally takes 
your tablets, contact your doctor, pharmacist or hospital for advice immediately. </p>
<p>Symptoms of overdose may include a forceful beating of the heart, an increased pulse rate or an 
increased blood pressure. 
If you forget to take Betmiga 
If you forget to take your medicine, take the missed dose as soon as you remember. If it is less than 
6 hours before your next scheduled dose, skip the dose and continue to take your medicine at the usual 
time. </p>
<p>Do not take a double dose to make up for a forgotten dose. If you miss several doses, tell your doctor 
and follow the advice given to you. </p>
<p>If you stop taking Betmiga 
Do not stop treatment with Betmiga early if you do not see an immediate effect. Your bladder might 
need some time to adapt. You should continue taking your tablets. Do not stop taking them when your 
bladder condition improves. Stopping treatment may result in recurrence of symptoms of overactive 
bladder. </p>
<p>Do not stop taking Betmiga without talking to your doctor first, as your overactive bladder symptoms 
may come back. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most serious side effects may include irregular heart beat (atrial fibrillation). This is an 
uncommon side effect (may affect up to 1 in 100 people), but if this side effect occurs, immediately 
stop taking the medicine and seek urgent medical advice. </p>
<p>If you get headaches, especially sudden, migraine-like (throbbing) headaches, tell your doctor. These 
may be signs of severely elevated blood pressure. </p>
<p>Other side effects include: </p>
<p>Common side effects (may affect up to 1 in 10 people) 
- Increased heart rate (tachycardia) 
- Infection of the structures that carry urine (urinary tract infections) 
- Nausea 
- Constipation 
- Headache 
- Diarrhoea 
- Dizziness </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
- Bladder infection (cystitis) 
- Feeling your heartbeat (palpitations) 
- Vaginal infection 
- Indigestion (dyspepsia) 
- Infection of the stomach (gastritis) 
- Swelling of the joints 
- Itching of the vulva or vagina (vulvovaginal pruritus) 
- Increased blood pressure 
- Increase in liver enzymes (GGT, AST and ALT) 
- Itching, rash or hives (urticaria, rash, rash macular, rash papular, pruritus) </p>
<p>Rare side effects (may affect up to 1 in 1,000 people) 
- Swelling of the eyelid (eyelid oedema) 
- Swelling of the lip (lip oedema) 
- Swelling of the deeper layers of the skin caused by a build-up of fluid, which can affect any part 
of the body including the face, tongue or throat and may cause difficulty in breathing 
(angioedema) 
- Small purple spots on the skin (purpura) 
- Inflammation of small blood vessels mainly affecting the skin (leukocytoclastic vasculitis) 
- Inability to completely empty the bladder (urinary retention) </p>
<p>Very rare side effects (may affect up to 1 in 10,000 people) 
- Hypertensive crisis </p>
<p>Not known side effects (frequency cannot be estimated from the available data) 
- Insomnia 
- Confusion </p>
<p>Betmiga may increase your chances of not being able to empty your bladder if you have bladder outlet 
obstruction or if you are taking other medicines to treat overactive bladder. Tell your doctor right away 
if you are unable to empty your bladder. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store betmiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store betmiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton or blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Betmiga contains 
- The active substance is mirabegron. 
Betmiga 25 mg prolonged-release tablets 
Each tablet contains 25 mg of mirabegron. 
Betmiga 50 mg prolonged-release tablets 
Each tablet contains 50 mg of mirabegron. 
- The other ingredients are: 
Tablet core: Macrogols, hydroxypropylcellulose, butylhydroxytoluene, magnesium stearate 
Film-coating: Hypromellose, macrogol, iron oxide yellow (E172), iron oxide red (E172) (25 mg 
tablet only). </p>
<p>What Betmiga looks like and contents of the pack 
Betmiga 25 mg prolonged release film-coated tablets are oval, brown film-coated tablets, debossed 
with the company logo and  325  on the same side. 
Betmiga 50 mg prolonged release film-coated tablets are oval, yellow film-coated tablets, debossed 
with the company logo and  355  on the same side. </p>
<p>Betmiga is available in aluminium-aluminium blister in packs containing 10, 20, 30, 50, 60, 90, 100 or 
200 tablets. </p>
<p>Not all pack sizes may be available in your country.  </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Astellas Pharma Europe B.V. 
Sylviusweg 2333 BE Leiden 
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Astellas Pharma B.V. Branch 
T l/Tel: +32 (0)2 5580Lietuva 
Biocodex UAB 
Tel.: +370 37 408   </p>
<p>Te .: +359 2 862 53 Luxembourg/Luxemburg 
Astellas Pharma B.V. Branch 
Belgique/Belgien 
T l/Tel: +32 (0)2 5580 esk  republika 
Astellas Pharma s.r.o. 
Tel: +420 221 401 Magyarorsz g 
Astellas Pharma Kft. 
Tel.: +36 1 577 8Danmark 
Astellas Pharma a/s 
Tlf: +45 43 430Malta 
Astellas Pharmaceuticals AEBE 
Tel: +30 210 8189Deutschland 
Astellas Pharma GmbH 
Tel.: +49 (0)89 454Nederland 
Astellas Pharma B.V. 
Tel: +31 (0)71 5455Eesti 
Biocodex O<br />
Tel: +372 6 056 Norge 
Astellas Pharma 
Tlf: +47 66 76 46 <br />
Astellas Pharmaceuticals AEBE 
 : +30 210 8189 sterreich 
Astellas Pharma Ges.m.b.H. 
Tel.: +43 (0)1 8772Espa a 
Astellas Pharma S.A. 
Tel: +34 91 4952Polska 
Astellas Pharma Sp.z.o.o. 
Tel.: +48 225451 France 
Astellas Pharma S.A.S. 
T l: +33 (0)1 55917Portugal 
Astellas Farma, Lda. 
Tel: +351 21 4401Hrvatska 
Astellas d.o.o 
Tel: +385 1670 0Rom nia 
S.C.Astellas Pharma SRL 
Tel: +40 (0)21 361 04 95/96/Ireland 
Astellas Pharma Co. Ltd. 
Tel: +353 (0)1 4671Slovenija 
Astellas Pharma d.o.o 
Tel: +386 14011 sland 
Vistor hf 
S mi: +354 535 7Slovensk  republika 
Astellas Pharma s.r.o. 
Tel: +421 2 4444 2Italia 
Astellas Pharma S.p.A. 
Tel: +39 (0)2 921Suomi/Finland 
Astellas Pharma 
Puh/Tel: +358 (0)9 85606  </p>
<p>Astellas Pharmaceuticals AEBE 
 : +30 210 8189Sverige 
Astellas Pharma AB 
Tel: +46 (0)40-650 15 Latvija 
Biocodex SIA 
Tel: +371 67 619United Kingdom (Northern Ireland) 
Astellas Pharma Co., Limited 
Free call from Northern Ireland: 0800 783 5International number: +353 (0)1 4671This leaflet was last revised in {MM/YYYY} </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>         </div>"""      



Instance: composition-da-f5fcc043447c207ce2e1eb4575399a55
InstanceOf: CompositionUvEpi
Title: "Composition for betmiga Package Leaflet"
Description:  "Composition for betmiga Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/12/809/001 - 006"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf5fcc043447c207ce2e1eb4575399a55)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - betmiga"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Betmiga 
3. Sådan skal du tage Betmiga 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What betmiga is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What betmiga is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Betmiga indeholder det aktive stof mirabegron. Det virker afslappende på blæremuskulaturen (er en 
såkaldt beta 3-adrenoceptoragonist), som nedsætter aktiviteten i en overaktiv blære og behandler de 
dermed forbundne symptomer. </p>
<p>Betmiga anvendes til behandling af symptomerne på en overaktiv blære hos voksne<br />
- med pludselig vandladningstrang (såkaldt imperiøs vandladning) 
- med vandladningstrang oftere end normalt (såkaldt øget vandladningshyppighed)<br />
- med manglende evne til at styre vandladningen (såkaldt urge-inkontinens) </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take betmiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take betmiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Betmiga 
- hvis du er allergisk over for  mirabegron eller et af de øvrige indholdsstoffer i Betmiga (angivet i 
punkt 6).<br />
- hvis du har meget højt ukontrolleret blodtryk. 
Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Betmiga 
- hvis du har problemer med at tømme din blære eller har en svag urinstråle eller hvis du er i 
behandling med andre lægemidler for overaktiv blære så som antikolinerge lægemidler.<br />
- hvis du har nyre- eller leverproblemer. Din læge kan være nødt til at reducere din dosis eller kan 
fortælle dig, at du ikke må tage Betmiga, især hvis du tager anden medicin, som f.eks. 
itraconazol, ketoconazol (svampeinfektioner), ritonavir (HIV) og clarithromycin (bakterielle 
infektioner). Fortæl din læge, hvilken anden medicin, du tager. 
-  hvis du har en EKG (hjertekurve)-uregelmæssighed kendt som QT-forlængelse, eller hvis du 
tager medicin, der vides at bevirke dette, såsom. * medicin, som anvendes mod unormal hjerterytme, som f.eks. quinidin, sotalol, 
procainamid, ibutilid, flecainid, dofetilid og amiodaron;  * medicin som anvendes mod høfeber;<br />
 * antipsykotika (lægemidler mod psykisk sygdom), som f.eks. thioridazin, mesoridazin, 
haloperidol og chlorpromazin;  * medicin, som anvendes mod infektion, som f.eks. pentamidin, moxifloxacin, 
erythromycin og clarithromycin. </p>
<p>Mirabegron kan få dit blodtryk til at stige eller forværre dit blodtryk, hvis du tidligere har haft højt 
blodtryk. Det anbefales, at din læge kontrollerer dit blodtryk, når du tager Mirabegron. 
Børn og unge 
Dette lægemiddel må ikke gives til børn og unge under 18 år, da Betmigas sikkerhed og virkning ikke 
er klarlagt for denne aldersgruppe. 
Brug af anden medicin sammen med Betmiga 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.  </p>
<p>Betmiga kan påvirke andre lægemidlers virkemåde, og andre lægemidler kan påvirke dette 
lægemiddels virkemåde. 
- Fortæl altid lægen, hvis du bruger thioridazin (et lægemiddel mod psykisk sygdom), propafenon 
eller flecainid (lægemidler mod unormal hjerterytme), imipramin eller desipramin (lægemidler 
mod depression). Lægen kan være nødt til at justere dosis af disse specifikke lægemidler. 
- Fortæl altid lægen, hvis du bruger digoxin (et lægemiddel mod hjertesvigt eller unormal 
hjerterytme). Lægen måler koncentrationen af dette lægemiddel i blodet. Hvis koncentrationen i 
blodet er uden for det ønskede interval, kan lægen justere digoxindosis. 
- Fortæl altid lægen, hvis du bruger dabigatran-etexilat (et lægemiddel som anvendes til at 
mindske risikoen for at få en blodprop i hjernen eller andre steder i kroppen hos voksne 
patienter, der har en unormal hjerterytme (atrieflimren) med andre risikofaktorer). Lægen kan 
være nødt til at justere dosis af dette lægemiddel. 
Graviditet og amning 
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, må du ikke tage 
Betmiga. </p>
<p>Hvis du ammer, skal du spørge din læge eller apoteket til råds, før du tager dette lægemiddel. Det er 
sandsynligt, at dette lægemiddel udskilles i modermælk. Du og din læge skal beslutte, om du skal tage 
Betmiga eller amme. Du må ikke gøre begge dele. 
Trafik- og arbejdssikkerhed 
Der er ingen oplysninger, der tyder på, at dette lægemiddel påvirker din evne til at føre motorkøretøj 
og betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take betmiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take betmiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid dette lægemiddel nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller på 
apoteket.  </p>
<p>Den sædvanlige dosis er én 50 mg tablet gennem munden én gang dagligt. Hvis du har nyre- eller 
leverproblemer, kan lægen være nødt til at reducere din dosis til én 25 mg tablet én gang dagligt. Du 
skal tage dette lægemiddel med væske og synke tabletten hel. Tabletten må ikke knuses eller tygges. 
Betmiga kan tages med eller uden mad. 
Hvis du har taget for meget Betmiga 
Hvis du har taget flere tabletter, end du er blevet bedt om at tage, eller hvis en anden er kommet til at 
tage dine tabletter, skal du straks kontakte din læge, apoteket eller en skadestue. </p>
<p>Symptomer på overdosering kan omfatte kraftig hjertebanken, øget puls eller øget blodtryk. </p>
<p>Hvis du har glemt at tage Betmiga 
Hvis du har glemt at tage din medicin, skal du tage den glemte dosis, så snart du kommer i tanke om 
det. Hvis der er mindre end 6 timer til din næste planlagte dosis, skal du springe den glemte dosis over 
og fortsætte med at tage din medicin på det sædvanlige tidspunkt.  </p>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Hvis du har glemt flere doser, 
skal du fortælle det til din læge og følge de råd, du får. 
Hvis du holder op med at tage Betmiga 
Stands ikke behandlingen med Betmiga før tid, hvis du ikke straks oplever en virkning. Din blære kan 
have brug for tilvænningstid. Du skal fortsætte med at tage dine tabletter. Hold ikke op med at tage 
dem ved bedring af din blæresygdom. Standsning af behandlingen kan resultere i tilbagevenden af 
symptomer på overaktiv blære. </p>
<p>Hold ikke op med at tage Betmiga uden først at tale med lægen, da dine symptomer på overaktiv blære 
kan vende tilbage. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De mest alvorlige bivirkninger kan omfatte uregelmæssig puls (atrieflimren). Dette er en ikke 
almindelig bivirkning (kan forekomme hos op til 1 ud af 100 personer), men opstår denne bivirkning, 
skal du straks stoppe med at tage lægemidlet og med det samme kontakte lægen. </p>
<p>Hvis du oplever hovedpine, især pludselig, migræne-lignende (dunkende) hovedpine, så kontakt din 
læge. Dette kan være symptomer på stærkt forhøjet blodtryk.  </p>
<p>Andre bivirkninger omfatter: </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer)<br />
- Øget puls (takykardi) 
- Infektion i de urinledende strukturer (urinvejsinfektioner) 
- Kvalme 
- Obstipation 
- Hovedpine 
- Diarré 
- Svimmelhed </p>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) 
- Blæreinfektion (cystitis) 
- Du mærker dine hjerteslag (palpitationer) 
- Skedeinfektion 
- Fordøjelsesproblemer (dyspepsi) 
- Maveinfektion (gastritis) 
- Hævede led 
- Kløe i de ydre kvindelige kønsorganer eller skeden (vulvovaginal pruritis) 
- Øget blodtryk 
- Stigning i niveauerne af leverenzymer (GGT, ASAT og ALAT)<br />
- Kløe, udslæt eller nældefeber (urticaria, udslæt, makuløst udslæt, papuløst udslæt, pruritus) </p>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer) 
- Hævet øjenlåg (øjenlågsødem) 
- Hævet læbe (læbeødem) 
- Hævelse af hudens dybere lag forårsaget af væskeophobning, hvilket kan påvirke alle dele af 
kroppen, herunder ansigt, tunge eller svælg, og kan forårsage åndedrætsbesvær (angioødem) 
- Små violette pletter på huden (purpura) 
- Betændelse i små blodkar, som hovedsagelig forekommer i huden (leukocytoklastisk vasculitis) 
- Manglende evne til at tømme blære helt (urinretention) </p>
<p>Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer) 
- Hypertensiv krise </p>
<p>Ikke kendt (hyppighed kan ikke estimeres ud fra forhåndenværende data) 
- Søvnløshed 
- Forvirring </p>
<p>Betmiga kan forøge din risiko for at ikke at kunne tømme blæren, hvis du har 
blæreudgangsobstruktion eller tager andre lægemidler til behandling af overaktiv blære. Fortæl straks 
lægen, hvis du ikke kan tømme din blære. 
Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store betmiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store betmiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen eller blisteren efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.  </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Betmiga indeholder:</p>
<ul>
<li>Det aktive stof er mirabegron. 
Betmiga 25 mg filmovertrukne depottabletter<br />
Hver tablet indeholder 25 mg mirabegron. 
Betmiga 50 mg filmovertrukne depottabletter<br />
Hver tablet indeholder 50 mg mirabegron. </li>
<li>Øvrige indholdsstoffer: 
Tabletkerne: Macrogoler, hydroxypropylcellulose, butylhydroxytoluen, magnesiumstearat 
Filmovertræk: Hypromellose, macrogol, jernoxidgult (E 172), jernoxidrødt (E 172) (kun 25 mg 
tablet). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Betmiga 25 mg filmovertrukne depottabletter er ovale, brune filmovertrukne tabletter præget med 
firmalogo og "325" på samme side.<br />
Betmiga 50 mg filmovertrukne depottabletter er ovale, gule filmovertrukne tabletter præget med 
firmalogo og "355" på samme side. </p>
<p>Betmiga fås i aluminium/aluminium-blistre i pakninger med 10, 20, 30, 50, 60, 90, 100 eller tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført i dit land. 
Indehaver af markedsføringstilladelsen 
Astellas Pharma Europe B.V. 
Sylviusweg 2333 BE Leiden 
Holland </p>
<p>Fremstiller 
Delpharm Meppel B.V. 
Hogemaat 2 
7942 JG Meppel 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Astellas Pharma B.V. Branch 
Tél/Tel: +32 (0)2 5580 
Lietuva 
Biocodex UAB 
Tel.: +370 37 408<br />
България 
Астелас Фарма ЕООД<br />
Teл.: +359 2 862 53  </p>
<p>Luxembourg/Luxemburg 
Astellas Pharma B.V. Branch 
Belgique/Belgien 
Tél/Tel: +32 (0)2 5580 
Česká republika 
Astellas Pharma s.r.o. 
Tel: +420 221 401<br />
Magyarország 
Astellas Pharma Kft. 
Tel.: +36 1 577 8 
Danmark 
Astellas Pharma a/s 
Tlf: +45 43 430 
Malta 
Astellas Pharmaceuticals AEBE 
Tel: +30 210 8189 
Deutschland 
Astellas Pharma GmbH 
Tel.: +49 (0)89 454 
Nederland 
Astellas Pharma B.V. 
Tel: +31 (0)71 5455 
Eesti 
Biocodex OÜ 
Tel: +372 6 056<br />
Norge 
Astellas Pharma<br />
Tlf: +47 66 76 46<br />
Ελλάδα 
Astellas Pharmaceuticals AEBE 
Τηλ: +30 210 8189 
Österreich 
Astellas Pharma Ges.m.b.H. 
Tel.: +43 (0)1 8772 </p>
<p>España 
Astellas Pharma S.A. 
Tel: +34 91 4952 
Polska 
Astellas Pharma Sp.z.o.o. 
Tel.: +48 225451<br />
France 
Astellas Pharma S.A.S. 
Tél: +33 (0)1 55917 
Portugal 
Astellas Farma, Lda. 
Tel: +351 21 4401 
Hrvatska 
Astellas d.o.o 
Tel: +385 1670 0<br />
România 
S.C.Astellas Pharma SRL 
Tel: +40 (0)21 361 04 95/96/ 
Ireland 
Astellas Pharma Co. Ltd. 
Tel: +353 (0)1 4671 
Slovenija 
Astellas Pharma d.o.o 
Tel: +386 14011 
Ísland 
Vistor hf 
Sími: +354 535 7000  </p>
<p>Slovenská republika 
Astellas Pharma s.r.o.<br />
Tel: +421 2 4444 2 
Italia 
Astellas Pharma S.p.A. 
Tel: +39 (0)2 921 
Suomi/Finland 
Astellas Pharma 
Puh/Tel: +358 (0)9 85606 
Κύπρος 
Ελλάδα 
Astellas Pharmaceuticals AEBE 
Τηλ: +30 210 8189 
Sverige 
Astellas Pharma AB 
Tel: +46 (0)40-650 15<br />
Latvija 
Biocodex SIATel: +371 67 619 
United Kingdom (Northern Ireland) 
Astellas Pharma Co., Limited 
Free call from Northern Ireland: 0800 783 5International number: +353 (0)1 4671 </p>
<p>Denne indlægsseddel blev senest ændret {DD/MM/ÅÅÅÅ}<br />
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
http://www.ema.europa.eu hjemmeside.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f5fcc043447c207ce2e1eb4575399a55
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for betmiga Package Leaflet for language en"
Description: "ePI document Bundle for betmiga Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f5fcc043447c207ce2e1eb4575399a55"
* entry[0].resource = composition-en-f5fcc043447c207ce2e1eb4575399a55

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf5fcc043447c207ce2e1eb4575399a55"
* entry[=].resource = mpf5fcc043447c207ce2e1eb4575399a55
                            
                    
Instance: bundlepackageleaflet-da-f5fcc043447c207ce2e1eb4575399a55
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for betmiga Package Leaflet for language da"
Description: "ePI document Bundle for betmiga Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f5fcc043447c207ce2e1eb4575399a55"
* entry[0].resource = composition-da-f5fcc043447c207ce2e1eb4575399a55

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf5fcc043447c207ce2e1eb4575399a55"
* entry[=].resource = mpf5fcc043447c207ce2e1eb4575399a55
                            
                    



Instance: mpf5fcc043447c207ce2e1eb4575399a55
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Betmiga 25 mg prolonged-release tablets"
Description: "Betmiga 25 mg prolonged-release tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/12/809/001 - 006"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Betmiga 25 mg prolonged-release tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: f5fcc043447c207ce2e1eb4575399a55ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "betmiga"

* status = #current
* mode = #working

* title = "List of all ePIs associated with betmiga"

* subject = Reference(mpf5fcc043447c207ce2e1eb4575399a55)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#betmiga "betmiga"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f5fcc043447c207ce2e1eb4575399a55) // betmiga en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f5fcc043447c207ce2e1eb4575399a55) // betmiga da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f5fcc043447c207ce2e1eb4575399a55
InstanceOf: List

* insert f5fcc043447c207ce2e1eb4575399a55ListRuleset
    